RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

Rhea-AI Summary

RAPT Therapeutics announced participation in key investor conferences throughout September 2022. The events include Citi’s 17th Annual Biopharma Conference on September 7, Wells Fargo Healthcare Conference on September 8 featuring a fireside chat with President and CEO Brian Wong, and H.C. Wainwright 24th Annual Global Investment Conference on September 12, available on-demand. RAPT is focused on developing small molecule therapies for inflammatory diseases and oncology, including drug candidates RPT193 and FLX475. For live webcasts, visit their website.

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September:

• Citi’s 17^th Annual Biopharma Conference – Investor one-on-ones on Wednesday, September 7, 2022
  
  
• Wells Fargo Healthcare Conference – Fireside chat with Brian Wong, M.D., Ph.D., RAPT’s President and CEO, on Thursday, September 8, 2022, at 1:55 p.m. ET
  
  
• H.C. Wainwright 24^th Annual Global Investment Conference – Company presentation and panel discussion on autoimmune/inflammatory diseases will be available on-demand on Monday, September 12, 2022
  

To access the live webcasts or subsequent archived recordings of the company panel discussion and presentations, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

FAQ

What investor conferences is RAPT participating in September 2022?

RAPT is participating in Citi’s 17th Annual Biopharma Conference on September 7, Wells Fargo Healthcare Conference on September 8, and H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

Who is speaking at the Wells Fargo Healthcare Conference for RAPT?

Brian Wong, M.D., Ph.D., RAPT’s President and CEO, will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 8, 2022.

Where can I access RAPT's conference presentations?

Live webcasts and archived recordings of RAPT's conference presentations can be accessed on their website.

What are the key drug candidates developed by RAPT Therapeutics?

RAPT is developing RPT193 and FLX475, targeting C-C motif chemokine receptor 4 (CCR4) for the treatment of inflammation and cancer.

What is the focus of RAPT Therapeutics?

RAPT Therapeutics focuses on discovering and developing oral small molecule therapies for significant unmet needs in inflammatory diseases and oncology.